Rule 3.8A

Appendix 3E

Daily share buy-back notice (except minimum holding buy-back and selective buy-back)

Information and documents given to ASX become ASX's property and may be made public.

Name	of entity	ABN/ARSN	
Sign	na Pharmaceuticals Limited		15 088 417 403
We (the entity) give ASX the following	information.	
Info	rmation about buy-back		
1	Type of buy-back	On-market buy-back	
2	Date Appendix 3C was given to ASX	13 September 2012 (Associated Appendix 2014)	3D dated 2 October
	al of all shares/units bought e been received, before, and	on, previous day	_
	<u>e</u>	· · · · · · · · · · · · · · · · · · ·	o which acceptances Previous day
	<u>e</u>	on, previous day	_

		Before p	reviou	s day	Previous day
5	If buy-back is an on-market buy-back	Highest \$0.8525	price	paid:	Highest price paid: \$0.8000
		Lawari			Lowest price paid: \$0.8100
		\$0.5600	price	paid:	Highest price allowed under rule 7.33: \$0.8453

How many shares/units may still be bought back?

6	If the company/trust has disclosed	15,739,777
	an intention to buy back a	
	maximum number of shares/units	
	- the remaining number of	
	shares/units to be bought back	
	-	

Compliance statement

- 1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

or, for trusts only:

Print name:

- 1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

(Director/Company secretary)

Sign here: Date: 16 June 2015

SUE MORGAN

== == == == ==